Esproquin is an α2-adrenergic receptor agonist derived from tetrahydroisoquinoline.[1] It has a positive inotropic effect, suggesting potential use in treatment of chronic heart failure.[2]
 | |
| Clinical data | |
|---|---|
| Other names | Esproquine |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H21NOS |
| Molar mass | 251.39 g·mol−1 |
| 3D model (JSmol) | |
| |
References
edit- ^ Gray AP, Shiley RH (July 1973). "Preparation and cardiovascular actions of a group of tetrahydroisoquinoline derivatives". Journal of Medicinal Chemistry. 16 (7): 859–61. doi:10.1021/jm00265a028. PMID 4146907.
- ^ Kotelanski B, Grozmann RJ, Cohn JN (1973). "Positive inotropic effect of oral esproquin in normal subjects". Clinical Pharmacology and Therapeutics. 14 (3): 427–33. doi:10.1002/cpt1973143427. PMID 4698571. S2CID 46266823.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |